Jazz Pharmaceuticals (JAZZ) Expected to Announce Quarterly Earnings on Wednesday

Jazz Pharmaceuticals (NASDAQ:JAZZ) is expected to issue its Q3 2025 results after the market closes on Wednesday, November 5th. Analysts expect the company to announce earnings of $5.87 per share and revenue of $1.1090 billion for the quarter. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS.Parties may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 4:30 PM ET.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The company had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The business’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $5.30 earnings per share. On average, analysts expect Jazz Pharmaceuticals to post $17 EPS for the current fiscal year and $19 EPS for the next fiscal year.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ:JAZZ opened at $138.13 on Wednesday. The company has a market cap of $8.38 billion, a P/E ratio of -20.52, a PEG ratio of 8.89 and a beta of 0.28. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. Jazz Pharmaceuticals has a one year low of $95.49 and a one year high of $148.06. The business’s 50-day simple moving average is $131.25 and its 200 day simple moving average is $117.51.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 3,500 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $140.00, for a total transaction of $490,000.00. Following the sale, the director directly owned 408,826 shares in the company, valued at $57,235,640. The trade was a 0.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders sold 11,500 shares of company stock worth $1,525,280. 4.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Vestal Point Capital LP acquired a new position in Jazz Pharmaceuticals during the 2nd quarter worth $127,344,000. AQR Capital Management LLC raised its stake in shares of Jazz Pharmaceuticals by 62.1% in the 2nd quarter. AQR Capital Management LLC now owns 794,770 shares of the specialty pharmaceutical company’s stock worth $84,341,000 after buying an additional 304,463 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Jazz Pharmaceuticals by 147.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company’s stock worth $43,652,000 after buying an additional 209,667 shares in the last quarter. Ameriprise Financial Inc. raised its stake in shares of Jazz Pharmaceuticals by 11.4% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company’s stock worth $198,159,000 after buying an additional 191,637 shares in the last quarter. Finally, Sofinnova Investments Inc. raised its stake in shares of Jazz Pharmaceuticals by 36.1% in the 2nd quarter. Sofinnova Investments Inc. now owns 694,096 shares of the specialty pharmaceutical company’s stock worth $73,657,000 after buying an additional 184,046 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Wall Street Analyst Weigh In

JAZZ has been the topic of several analyst reports. Royal Bank Of Canada raised their target price on Jazz Pharmaceuticals from $145.00 to $151.00 and gave the company an “outperform” rating in a report on Thursday, August 28th. Zacks Research upgraded Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Friday, August 15th. Morgan Stanley set a $183.00 target price on Jazz Pharmaceuticals in a report on Friday. Needham & Company LLC reiterated a “buy” rating and set a $202.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, August 28th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Jazz Pharmaceuticals in a report on Wednesday, October 8th. Fourteen analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $179.33.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.